Flatwing fails to shift attorney fees to Pfizer unit, Anacor

29-06-2021

Muireann Bolger

Flatwing fails to shift attorney fees to Pfizer unit, Anacor

nitpicker / Shutterstock.com

Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.


Pfizer, Anacor, Flatwing, PTAB, patents, Kerydin

LSIPR